Interpace Biosciences (OTC: IDXG) reported Q2 EPS of $0.09, $0.17 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $11.03 million versus the consensus estimate of $13 million.

For earnings history and earnings-related data on Interpace Biosciences (IDXG) click here.